Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Japan.
Department of Ophthalmology, Tohoku University Graduate School of Medicine, Japan.
Intern Med. 2022 Oct 15;61(20):3101-3106. doi: 10.2169/internalmedicine.0104-22. Epub 2022 Aug 10.
BNT162b2 (Pfizer/BioNTech) is a coronavirus disease 2019 (COVID-19) vaccine containing nucleoside-modified messenger RNA encoding the severe acute respiratory syndrome coronavirus 2 spike glycoprotein. Recently, ocular complications of mRNA vaccines have been reported increasingly frequently. However, immunological adverse events due to mRNA vaccines in real-world settings are not fully known. We herein report the novel development of sarcoidosis manifested as uveitis, bilateral hilar lymphadenopathy, angiotensin-converting enzyme elevation, and epithelioid and giant cell granuloma formation in the lung soon after the first BNT162b2 injection and review the current literature, including three reported cases of sarcoid-like reaction following COVID-19 vaccination.
BNT162b2(辉瑞/生物科技)是一种含有修饰核苷的信使 RNA 的新型冠状病毒病 2019(COVID-19)疫苗,编码严重急性呼吸系统综合征冠状病毒 2 刺突糖蛋白。最近,越来越频繁地报道了信使 RNA 疫苗的眼部并发症。然而,在真实环境中,由于信使 RNA 疫苗引起的免疫不良反应尚不完全清楚。我们在此报告首例 BNT162b2 注射后不久即出现葡萄膜炎、双侧肺门淋巴结肿大、血管紧张素转换酶升高以及肺内上皮样和巨细胞肉芽肿形成的新型结节病表现,并复习了目前的文献,包括 3 例 COVID-19 疫苗接种后类似结节病反应的报道。